Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation-Reference-Cited by-同舟云学术

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Published:2017-11-30 Issue:3 Volume:97 Page:435-441
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Kuykendall Andrew T.,Shah Savan,Talati Chetasi,Al Ali Najla,Sweet Kendra,Padron Eric,Sallman David A.,Lancet Jeffrey E.,List Alan F.,Zuckerman Kenneth S.,Komrokji Rami S.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3194-4/fulltext.html

Reference20 articles.

1. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807. https://doi.org/10.1056/NEJMoa1110557

2. Harrison C, Kiladjian JJ, al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798. https://doi.org/10.1056/NEJMoa1110556

3. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 123(12):1833–1835. https://doi.org/10.1182/blood-2013-12-544411

4. Harrison CN, Vannucchi AM, Kiladjian JJ, al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701–1707. https://doi.org/10.1038/leu.2016.148

5. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, For the COMFORT-I investigators (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100(4):479–488. https://doi.org/10.3324/haematol.2014.115840

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ph-Negative Chronic Myeloproliferative Neoplasms;Reference Module in Biomedical Sciences;2024

2. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis;Expert Opinion on Investigational Drugs;2023-10-03

3. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group;Clinical and Experimental Medicine;2023-09-25

4. New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐X_L/BCL‐2 inhibition with navitoclax;Cancer;2023-08-16

5. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy;Expert Opinion on Pharmacotherapy;2023-05-29